JAMA ONCOL 润色咨询

JAMA Oncology

出版年份：暂无数据 年文章数：1010 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：1.9% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2130637, encodeId=25b9213063e46, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：分享JAMA Oncology的投稿经历，顶刊效率高，回复快，祝大家投稿顺利！ 2022.8.7 submit 2022.8.7 QC 2022.8.8 Under review 2022.10.10 催稿 2022.10.11 邮件回复在等第三个reviewer意见 2022.11.04 一审结果--修回 3个审稿人，意见非常多且细致，总体均给出了较positive评价，最后编辑给了2-3周时间修回，申请延期一周 2022.11.04--11.30 修改论文+润色 2022.12.01 R1 resubmit 2022.12.01 QC 2022.12.02 Under review 2023.1.10 accept！ 最后也祝大家投稿文章顺利接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Sat May 06 22:41:43 CST 2023, time=2023-05-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2121136, encodeId=f1eb212113662, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：大神们，咨询下，这个杂志，投letter接收后，多久才出proofs, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23963312341, createdName=朝天之阙, createdTime=Wed Mar 22 16:29:21 CST 2023, time=2023-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=916104, encodeId=2063916104d7, content=收中药注射液文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d4a1696282, createdName=王学谦, createdTime=Wed Jan 13 00:02:30 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094828, encodeId=cc3f2094828b0, content=收个案吗 有大神有经验吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=022e5557503, createdName=blossom777, createdTime=Wed Oct 19 22:14:04 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116018, encodeId=fe212116018f8, content=偏重的研究方向：肺癌;Oncology<br>经验分享：请问大家投稿以后收到杂志的邮件了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=ms6000001877480263, createdTime=Thu Feb 23 01:35:11 CST 2023, time=2023-02-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1106766, encodeId=11551106e6640, content=上传文章时应该上传word还是pdf？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106765, encodeId=8b941106e6535, content=文章应该如何上传？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584746, encodeId=65f1584e4659, content=你会弄了吗<span class="quote">156****8060暂无昵称 2020-01-16 00:00:00 发表:<br>老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议</span>, beContent=156****8060暂无昵称 2020-01-16 00:00:00 发表: 老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Fri Feb 14 00:00:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572642, encodeId=48d65e2642d5, content=22.416分，还怕什么<span class="quote">sunliang 2019-04-17 发表::<br>这个杂志分区是0区？</span><span class="quote">sunliang 2019-04-17 00:00:00 发表:<br>这个杂志分区是0区？</span>, beContent=sunliang 2019-04-17 发表:: 这个杂志分区是0区？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569677, encodeId=4fe15696e774, content=这个杂志分区是0区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=375, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Wed Apr 17 00:00:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
    2023-05-06 Oncosurgeon-J 来自上海

    审稿速度:3.0 | 投稿命中率:5.0
    偏重的研究方向：肿瘤
    经验分享：分享JAMA Oncology的投稿经历，顶刊效率高，回复快，祝大家投稿顺利！ 2022.8.7 submit 2022.8.7 QC 2022.8.8 Under review 2022.10.10 催稿 2022.10.11 邮件回复在等第三个reviewer意见 2022.11.04 一审结果--修回 3个审稿人，意见非常多且细致，总体均给出了较positive评价，最后编辑给了2-3周时间修回，申请延期一周 2022.11.04--11.30 修改论文+润色 2022.12.01 R1 resubmit 2022.12.01 QC 2022.12.02 Under review 2023.1.10 accept！ 最后也祝大家投稿文章顺利接收！

    7

    展开7条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2130637, encodeId=25b9213063e46, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：分享JAMA Oncology的投稿经历，顶刊效率高，回复快，祝大家投稿顺利！ 2022.8.7 submit 2022.8.7 QC 2022.8.8 Under review 2022.10.10 催稿 2022.10.11 邮件回复在等第三个reviewer意见 2022.11.04 一审结果--修回 3个审稿人，意见非常多且细致，总体均给出了较positive评价，最后编辑给了2-3周时间修回，申请延期一周 2022.11.04--11.30 修改论文+润色 2022.12.01 R1 resubmit 2022.12.01 QC 2022.12.02 Under review 2023.1.10 accept！ 最后也祝大家投稿文章顺利接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Sat May 06 22:41:43 CST 2023, time=2023-05-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2121136, encodeId=f1eb212113662, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：大神们，咨询下，这个杂志，投letter接收后，多久才出proofs, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23963312341, createdName=朝天之阙, createdTime=Wed Mar 22 16:29:21 CST 2023, time=2023-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=916104, encodeId=2063916104d7, content=收中药注射液文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d4a1696282, createdName=王学谦, createdTime=Wed Jan 13 00:02:30 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094828, encodeId=cc3f2094828b0, content=收个案吗 有大神有经验吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=022e5557503, createdName=blossom777, createdTime=Wed Oct 19 22:14:04 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116018, encodeId=fe212116018f8, content=偏重的研究方向：肺癌;Oncology<br>经验分享：请问大家投稿以后收到杂志的邮件了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=ms6000001877480263, createdTime=Thu Feb 23 01:35:11 CST 2023, time=2023-02-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1106766, encodeId=11551106e6640, content=上传文章时应该上传word还是pdf？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106765, encodeId=8b941106e6535, content=文章应该如何上传？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584746, encodeId=65f1584e4659, content=你会弄了吗<span class="quote">156****8060暂无昵称 2020-01-16 00:00:00 发表:<br>老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议</span>, beContent=156****8060暂无昵称 2020-01-16 00:00:00 发表: 老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Fri Feb 14 00:00:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572642, encodeId=48d65e2642d5, content=22.416分，还怕什么<span class="quote">sunliang 2019-04-17 发表::<br>这个杂志分区是0区？</span><span class="quote">sunliang 2019-04-17 00:00:00 发表:<br>这个杂志分区是0区？</span>, beContent=sunliang 2019-04-17 发表:: 这个杂志分区是0区？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569677, encodeId=4fe15696e774, content=这个杂志分区是0区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=375, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Wed Apr 17 00:00:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
    2023-03-22 朝天之阙 来自广西

    审稿速度:1.0 | 投稿命中率:75.0
    经验分享：大神们，咨询下，这个杂志，投letter接收后，多久才出proofs

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2130637, encodeId=25b9213063e46, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：分享JAMA Oncology的投稿经历，顶刊效率高，回复快，祝大家投稿顺利！ 2022.8.7 submit 2022.8.7 QC 2022.8.8 Under review 2022.10.10 催稿 2022.10.11 邮件回复在等第三个reviewer意见 2022.11.04 一审结果--修回 3个审稿人，意见非常多且细致，总体均给出了较positive评价，最后编辑给了2-3周时间修回，申请延期一周 2022.11.04--11.30 修改论文+润色 2022.12.01 R1 resubmit 2022.12.01 QC 2022.12.02 Under review 2023.1.10 accept！ 最后也祝大家投稿文章顺利接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Sat May 06 22:41:43 CST 2023, time=2023-05-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2121136, encodeId=f1eb212113662, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：大神们，咨询下，这个杂志，投letter接收后，多久才出proofs, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23963312341, createdName=朝天之阙, createdTime=Wed Mar 22 16:29:21 CST 2023, time=2023-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=916104, encodeId=2063916104d7, content=收中药注射液文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d4a1696282, createdName=王学谦, createdTime=Wed Jan 13 00:02:30 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094828, encodeId=cc3f2094828b0, content=收个案吗 有大神有经验吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=022e5557503, createdName=blossom777, createdTime=Wed Oct 19 22:14:04 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116018, encodeId=fe212116018f8, content=偏重的研究方向：肺癌;Oncology<br>经验分享：请问大家投稿以后收到杂志的邮件了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=ms6000001877480263, createdTime=Thu Feb 23 01:35:11 CST 2023, time=2023-02-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1106766, encodeId=11551106e6640, content=上传文章时应该上传word还是pdf？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106765, encodeId=8b941106e6535, content=文章应该如何上传？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584746, encodeId=65f1584e4659, content=你会弄了吗<span class="quote">156****8060暂无昵称 2020-01-16 00:00:00 发表:<br>老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议</span>, beContent=156****8060暂无昵称 2020-01-16 00:00:00 发表: 老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Fri Feb 14 00:00:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572642, encodeId=48d65e2642d5, content=22.416分，还怕什么<span class="quote">sunliang 2019-04-17 发表::<br>这个杂志分区是0区？</span><span class="quote">sunliang 2019-04-17 00:00:00 发表:<br>这个杂志分区是0区？</span>, beContent=sunliang 2019-04-17 发表:: 这个杂志分区是0区？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569677, encodeId=4fe15696e774, content=这个杂志分区是0区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=375, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Wed Apr 17 00:00:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
    2021-01-13 王学谦

    收中药注射液文章吗

    2

    展开2条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2130637, encodeId=25b9213063e46, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：分享JAMA Oncology的投稿经历，顶刊效率高，回复快，祝大家投稿顺利！ 2022.8.7 submit 2022.8.7 QC 2022.8.8 Under review 2022.10.10 催稿 2022.10.11 邮件回复在等第三个reviewer意见 2022.11.04 一审结果--修回 3个审稿人，意见非常多且细致，总体均给出了较positive评价，最后编辑给了2-3周时间修回，申请延期一周 2022.11.04--11.30 修改论文+润色 2022.12.01 R1 resubmit 2022.12.01 QC 2022.12.02 Under review 2023.1.10 accept！ 最后也祝大家投稿文章顺利接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Sat May 06 22:41:43 CST 2023, time=2023-05-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2121136, encodeId=f1eb212113662, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：大神们，咨询下，这个杂志，投letter接收后，多久才出proofs, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23963312341, createdName=朝天之阙, createdTime=Wed Mar 22 16:29:21 CST 2023, time=2023-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=916104, encodeId=2063916104d7, content=收中药注射液文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d4a1696282, createdName=王学谦, createdTime=Wed Jan 13 00:02:30 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094828, encodeId=cc3f2094828b0, content=收个案吗 有大神有经验吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=022e5557503, createdName=blossom777, createdTime=Wed Oct 19 22:14:04 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116018, encodeId=fe212116018f8, content=偏重的研究方向：肺癌;Oncology<br>经验分享：请问大家投稿以后收到杂志的邮件了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=ms6000001877480263, createdTime=Thu Feb 23 01:35:11 CST 2023, time=2023-02-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1106766, encodeId=11551106e6640, content=上传文章时应该上传word还是pdf？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106765, encodeId=8b941106e6535, content=文章应该如何上传？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584746, encodeId=65f1584e4659, content=你会弄了吗<span class="quote">156****8060暂无昵称 2020-01-16 00:00:00 发表:<br>老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议</span>, beContent=156****8060暂无昵称 2020-01-16 00:00:00 发表: 老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Fri Feb 14 00:00:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572642, encodeId=48d65e2642d5, content=22.416分，还怕什么<span class="quote">sunliang 2019-04-17 发表::<br>这个杂志分区是0区？</span><span class="quote">sunliang 2019-04-17 00:00:00 发表:<br>这个杂志分区是0区？</span>, beContent=sunliang 2019-04-17 发表:: 这个杂志分区是0区？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569677, encodeId=4fe15696e774, content=这个杂志分区是0区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=375, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Wed Apr 17 00:00:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
    2022-10-19 blossom777

    收个案吗 有大神有经验吗😭

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2130637, encodeId=25b9213063e46, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：分享JAMA Oncology的投稿经历，顶刊效率高，回复快，祝大家投稿顺利！ 2022.8.7 submit 2022.8.7 QC 2022.8.8 Under review 2022.10.10 催稿 2022.10.11 邮件回复在等第三个reviewer意见 2022.11.04 一审结果--修回 3个审稿人，意见非常多且细致，总体均给出了较positive评价，最后编辑给了2-3周时间修回，申请延期一周 2022.11.04--11.30 修改论文+润色 2022.12.01 R1 resubmit 2022.12.01 QC 2022.12.02 Under review 2023.1.10 accept！ 最后也祝大家投稿文章顺利接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Sat May 06 22:41:43 CST 2023, time=2023-05-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2121136, encodeId=f1eb212113662, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：大神们，咨询下，这个杂志，投letter接收后，多久才出proofs, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23963312341, createdName=朝天之阙, createdTime=Wed Mar 22 16:29:21 CST 2023, time=2023-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=916104, encodeId=2063916104d7, content=收中药注射液文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d4a1696282, createdName=王学谦, createdTime=Wed Jan 13 00:02:30 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094828, encodeId=cc3f2094828b0, content=收个案吗 有大神有经验吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=022e5557503, createdName=blossom777, createdTime=Wed Oct 19 22:14:04 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116018, encodeId=fe212116018f8, content=偏重的研究方向：肺癌;Oncology<br>经验分享：请问大家投稿以后收到杂志的邮件了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=ms6000001877480263, createdTime=Thu Feb 23 01:35:11 CST 2023, time=2023-02-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1106766, encodeId=11551106e6640, content=上传文章时应该上传word还是pdf？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106765, encodeId=8b941106e6535, content=文章应该如何上传？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584746, encodeId=65f1584e4659, content=你会弄了吗<span class="quote">156****8060暂无昵称 2020-01-16 00:00:00 发表:<br>老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议</span>, beContent=156****8060暂无昵称 2020-01-16 00:00:00 发表: 老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Fri Feb 14 00:00:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572642, encodeId=48d65e2642d5, content=22.416分，还怕什么<span class="quote">sunliang 2019-04-17 发表::<br>这个杂志分区是0区？</span><span class="quote">sunliang 2019-04-17 00:00:00 发表:<br>这个杂志分区是0区？</span>, beContent=sunliang 2019-04-17 发表:: 这个杂志分区是0区？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569677, encodeId=4fe15696e774, content=这个杂志分区是0区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=375, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Wed Apr 17 00:00:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
    2023-02-23 ms6000001877480263 来自四川省

    偏重的研究方向：肺癌;Oncology
    经验分享：请问大家投稿以后收到杂志的邮件了吗？

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2130637, encodeId=25b9213063e46, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：分享JAMA Oncology的投稿经历，顶刊效率高，回复快，祝大家投稿顺利！ 2022.8.7 submit 2022.8.7 QC 2022.8.8 Under review 2022.10.10 催稿 2022.10.11 邮件回复在等第三个reviewer意见 2022.11.04 一审结果--修回 3个审稿人，意见非常多且细致，总体均给出了较positive评价，最后编辑给了2-3周时间修回，申请延期一周 2022.11.04--11.30 修改论文+润色 2022.12.01 R1 resubmit 2022.12.01 QC 2022.12.02 Under review 2023.1.10 accept！ 最后也祝大家投稿文章顺利接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Sat May 06 22:41:43 CST 2023, time=2023-05-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2121136, encodeId=f1eb212113662, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：大神们，咨询下，这个杂志，投letter接收后，多久才出proofs, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23963312341, createdName=朝天之阙, createdTime=Wed Mar 22 16:29:21 CST 2023, time=2023-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=916104, encodeId=2063916104d7, content=收中药注射液文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d4a1696282, createdName=王学谦, createdTime=Wed Jan 13 00:02:30 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094828, encodeId=cc3f2094828b0, content=收个案吗 有大神有经验吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=022e5557503, createdName=blossom777, createdTime=Wed Oct 19 22:14:04 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116018, encodeId=fe212116018f8, content=偏重的研究方向：肺癌;Oncology<br>经验分享：请问大家投稿以后收到杂志的邮件了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=ms6000001877480263, createdTime=Thu Feb 23 01:35:11 CST 2023, time=2023-02-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1106766, encodeId=11551106e6640, content=上传文章时应该上传word还是pdf？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106765, encodeId=8b941106e6535, content=文章应该如何上传？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584746, encodeId=65f1584e4659, content=你会弄了吗<span class="quote">156****8060暂无昵称 2020-01-16 00:00:00 发表:<br>老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议</span>, beContent=156****8060暂无昵称 2020-01-16 00:00:00 发表: 老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Fri Feb 14 00:00:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572642, encodeId=48d65e2642d5, content=22.416分，还怕什么<span class="quote">sunliang 2019-04-17 发表::<br>这个杂志分区是0区？</span><span class="quote">sunliang 2019-04-17 00:00:00 发表:<br>这个杂志分区是0区？</span>, beContent=sunliang 2019-04-17 发表:: 这个杂志分区是0区？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569677, encodeId=4fe15696e774, content=这个杂志分区是0区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=375, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Wed Apr 17 00:00:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
    2021-12-27 rayms

    上传文章时应该上传word还是pdf？

    2

    展开2条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2130637, encodeId=25b9213063e46, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：分享JAMA Oncology的投稿经历，顶刊效率高，回复快，祝大家投稿顺利！ 2022.8.7 submit 2022.8.7 QC 2022.8.8 Under review 2022.10.10 催稿 2022.10.11 邮件回复在等第三个reviewer意见 2022.11.04 一审结果--修回 3个审稿人，意见非常多且细致，总体均给出了较positive评价，最后编辑给了2-3周时间修回，申请延期一周 2022.11.04--11.30 修改论文+润色 2022.12.01 R1 resubmit 2022.12.01 QC 2022.12.02 Under review 2023.1.10 accept！ 最后也祝大家投稿文章顺利接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Sat May 06 22:41:43 CST 2023, time=2023-05-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2121136, encodeId=f1eb212113662, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：大神们，咨询下，这个杂志，投letter接收后，多久才出proofs, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23963312341, createdName=朝天之阙, createdTime=Wed Mar 22 16:29:21 CST 2023, time=2023-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=916104, encodeId=2063916104d7, content=收中药注射液文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d4a1696282, createdName=王学谦, createdTime=Wed Jan 13 00:02:30 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094828, encodeId=cc3f2094828b0, content=收个案吗 有大神有经验吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=022e5557503, createdName=blossom777, createdTime=Wed Oct 19 22:14:04 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116018, encodeId=fe212116018f8, content=偏重的研究方向：肺癌;Oncology<br>经验分享：请问大家投稿以后收到杂志的邮件了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=ms6000001877480263, createdTime=Thu Feb 23 01:35:11 CST 2023, time=2023-02-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1106766, encodeId=11551106e6640, content=上传文章时应该上传word还是pdf？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106765, encodeId=8b941106e6535, content=文章应该如何上传？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584746, encodeId=65f1584e4659, content=你会弄了吗<span class="quote">156****8060暂无昵称 2020-01-16 00:00:00 发表:<br>老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议</span>, beContent=156****8060暂无昵称 2020-01-16 00:00:00 发表: 老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Fri Feb 14 00:00:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572642, encodeId=48d65e2642d5, content=22.416分，还怕什么<span class="quote">sunliang 2019-04-17 发表::<br>这个杂志分区是0区？</span><span class="quote">sunliang 2019-04-17 00:00:00 发表:<br>这个杂志分区是0区？</span>, beContent=sunliang 2019-04-17 发表:: 这个杂志分区是0区？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569677, encodeId=4fe15696e774, content=这个杂志分区是0区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=375, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Wed Apr 17 00:00:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
    2021-12-28 小动量

    文章应该如何上传？

    1

    展开1条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2130637, encodeId=25b9213063e46, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：分享JAMA Oncology的投稿经历，顶刊效率高，回复快，祝大家投稿顺利！ 2022.8.7 submit 2022.8.7 QC 2022.8.8 Under review 2022.10.10 催稿 2022.10.11 邮件回复在等第三个reviewer意见 2022.11.04 一审结果--修回 3个审稿人，意见非常多且细致，总体均给出了较positive评价，最后编辑给了2-3周时间修回，申请延期一周 2022.11.04--11.30 修改论文+润色 2022.12.01 R1 resubmit 2022.12.01 QC 2022.12.02 Under review 2023.1.10 accept！ 最后也祝大家投稿文章顺利接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Sat May 06 22:41:43 CST 2023, time=2023-05-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2121136, encodeId=f1eb212113662, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：大神们，咨询下，这个杂志，投letter接收后，多久才出proofs, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23963312341, createdName=朝天之阙, createdTime=Wed Mar 22 16:29:21 CST 2023, time=2023-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=916104, encodeId=2063916104d7, content=收中药注射液文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d4a1696282, createdName=王学谦, createdTime=Wed Jan 13 00:02:30 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094828, encodeId=cc3f2094828b0, content=收个案吗 有大神有经验吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=022e5557503, createdName=blossom777, createdTime=Wed Oct 19 22:14:04 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116018, encodeId=fe212116018f8, content=偏重的研究方向：肺癌;Oncology<br>经验分享：请问大家投稿以后收到杂志的邮件了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=ms6000001877480263, createdTime=Thu Feb 23 01:35:11 CST 2023, time=2023-02-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1106766, encodeId=11551106e6640, content=上传文章时应该上传word还是pdf？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106765, encodeId=8b941106e6535, content=文章应该如何上传？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584746, encodeId=65f1584e4659, content=你会弄了吗<span class="quote">156****8060暂无昵称 2020-01-16 00:00:00 发表:<br>老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议</span>, beContent=156****8060暂无昵称 2020-01-16 00:00:00 发表: 老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Fri Feb 14 00:00:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572642, encodeId=48d65e2642d5, content=22.416分，还怕什么<span class="quote">sunliang 2019-04-17 发表::<br>这个杂志分区是0区？</span><span class="quote">sunliang 2019-04-17 00:00:00 发表:<br>这个杂志分区是0区？</span>, beContent=sunliang 2019-04-17 发表:: 这个杂志分区是0区？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569677, encodeId=4fe15696e774, content=这个杂志分区是0区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=375, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Wed Apr 17 00:00:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
    2020-02-14 1e2321c7m65(暂无匿称)

    你会弄了吗156****8060暂无昵称 2020-01-16 00:00:00 发表:
    老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议

    156****8060暂无昵称 2020-01-16 00:00:00 发表: 老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2130637, encodeId=25b9213063e46, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：分享JAMA Oncology的投稿经历，顶刊效率高，回复快，祝大家投稿顺利！ 2022.8.7 submit 2022.8.7 QC 2022.8.8 Under review 2022.10.10 催稿 2022.10.11 邮件回复在等第三个reviewer意见 2022.11.04 一审结果--修回 3个审稿人，意见非常多且细致，总体均给出了较positive评价，最后编辑给了2-3周时间修回，申请延期一周 2022.11.04--11.30 修改论文+润色 2022.12.01 R1 resubmit 2022.12.01 QC 2022.12.02 Under review 2023.1.10 accept！ 最后也祝大家投稿文章顺利接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Sat May 06 22:41:43 CST 2023, time=2023-05-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2121136, encodeId=f1eb212113662, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：大神们，咨询下，这个杂志，投letter接收后，多久才出proofs, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23963312341, createdName=朝天之阙, createdTime=Wed Mar 22 16:29:21 CST 2023, time=2023-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=916104, encodeId=2063916104d7, content=收中药注射液文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d4a1696282, createdName=王学谦, createdTime=Wed Jan 13 00:02:30 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094828, encodeId=cc3f2094828b0, content=收个案吗 有大神有经验吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=022e5557503, createdName=blossom777, createdTime=Wed Oct 19 22:14:04 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116018, encodeId=fe212116018f8, content=偏重的研究方向：肺癌;Oncology<br>经验分享：请问大家投稿以后收到杂志的邮件了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=ms6000001877480263, createdTime=Thu Feb 23 01:35:11 CST 2023, time=2023-02-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1106766, encodeId=11551106e6640, content=上传文章时应该上传word还是pdf？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106765, encodeId=8b941106e6535, content=文章应该如何上传？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584746, encodeId=65f1584e4659, content=你会弄了吗<span class="quote">156****8060暂无昵称 2020-01-16 00:00:00 发表:<br>老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议</span>, beContent=156****8060暂无昵称 2020-01-16 00:00:00 发表: 老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Fri Feb 14 00:00:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572642, encodeId=48d65e2642d5, content=22.416分，还怕什么<span class="quote">sunliang 2019-04-17 发表::<br>这个杂志分区是0区？</span><span class="quote">sunliang 2019-04-17 00:00:00 发表:<br>这个杂志分区是0区？</span>, beContent=sunliang 2019-04-17 发表:: 这个杂志分区是0区？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569677, encodeId=4fe15696e774, content=这个杂志分区是0区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=375, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Wed Apr 17 00:00:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
    2019-06-21 lovetcm

    22.416分，还怕什么sunliang 2019-04-17 发表::
    这个杂志分区是0区？    sunliang 2019-04-17 00:00:00 发表:
    这个杂志分区是0区？

    sunliang 2019-04-17 发表:: 这个杂志分区是0区？

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2130637, encodeId=25b9213063e46, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：分享JAMA Oncology的投稿经历，顶刊效率高，回复快，祝大家投稿顺利！ 2022.8.7 submit 2022.8.7 QC 2022.8.8 Under review 2022.10.10 催稿 2022.10.11 邮件回复在等第三个reviewer意见 2022.11.04 一审结果--修回 3个审稿人，意见非常多且细致，总体均给出了较positive评价，最后编辑给了2-3周时间修回，申请延期一周 2022.11.04--11.30 修改论文+润色 2022.12.01 R1 resubmit 2022.12.01 QC 2022.12.02 Under review 2023.1.10 accept！ 最后也祝大家投稿文章顺利接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Sat May 06 22:41:43 CST 2023, time=2023-05-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2121136, encodeId=f1eb212113662, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：大神们，咨询下，这个杂志，投letter接收后，多久才出proofs, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23963312341, createdName=朝天之阙, createdTime=Wed Mar 22 16:29:21 CST 2023, time=2023-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=916104, encodeId=2063916104d7, content=收中药注射液文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d4a1696282, createdName=王学谦, createdTime=Wed Jan 13 00:02:30 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094828, encodeId=cc3f2094828b0, content=收个案吗 有大神有经验吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=022e5557503, createdName=blossom777, createdTime=Wed Oct 19 22:14:04 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116018, encodeId=fe212116018f8, content=偏重的研究方向：肺癌;Oncology<br>经验分享：请问大家投稿以后收到杂志的邮件了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=ms6000001877480263, createdTime=Thu Feb 23 01:35:11 CST 2023, time=2023-02-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1106766, encodeId=11551106e6640, content=上传文章时应该上传word还是pdf？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106765, encodeId=8b941106e6535, content=文章应该如何上传？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584746, encodeId=65f1584e4659, content=你会弄了吗<span class="quote">156****8060暂无昵称 2020-01-16 00:00:00 发表:<br>老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议</span>, beContent=156****8060暂无昵称 2020-01-16 00:00:00 发表: 老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Fri Feb 14 00:00:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572642, encodeId=48d65e2642d5, content=22.416分，还怕什么<span class="quote">sunliang 2019-04-17 发表::<br>这个杂志分区是0区？</span><span class="quote">sunliang 2019-04-17 00:00:00 发表:<br>这个杂志分区是0区？</span>, beContent=sunliang 2019-04-17 发表:: 这个杂志分区是0区？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569677, encodeId=4fe15696e774, content=这个杂志分区是0区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=375, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Wed Apr 17 00:00:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
    2019-04-17 sunliang

    这个杂志分区是0区？

    0

共30条页码: 1/3页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分